Kelly Moynihan, PhD

VP, CSO Partner Team at Curie.Bio

Speaker

Kelly Moynihan, PhD, has a background in biotech company creation and venture capital. While at Third Rock Ventures, Kelly was involved in the formation and launch of multiple companies in the immunology space, including Celsius Therapeutics, Abata Therapeutics, and Asher Biotherapeutics. After the launch of Asher, she joined full time and operated for 4 years as Program Team Lead for AB248, leading the project from initiation through IND filing and 18 months of clinical development. Kelly Moynihan is now a VP at Curie.Bio, a seed stage investment firm with a unique co-piloting model that offers operational and strategic support for innovative therapeutics companies.